Consolidated Statement of Changes in Stockholders' (Deficit) Equity - USD ($) $ in Thousands	Total	TopoTarget	Forendo Pharma Ltd.	Common Stock	Common Stock TopoTarget	Common Stock Forendo Pharma Ltd.	Additional Paid-In Capital	Additional Paid-In Capital TopoTarget	Additional Paid-In Capital Forendo Pharma Ltd.	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance (shares) at Dec. 31, 2012				29,937,669
Beginning balance at Dec. 31, 2012	$ 6,621			$ 30			$ 257,078			$ 641	$ (251,128)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock to employees and Board of Director members (shares)				95,645
Issuance of restricted stock to employees and Board of Director members	0
Stock-based compensation expense	1,992						1,992
Issuance of common stock, net of offering costs (shares)				312,450	688,717
Issuance of common stock, net of offering costs	792	$ 1,543			$ 1		792	$ 1,542
Issuance of common stock and warrants, net of offering costs (shares)				6,000,000
Issuance of common stock and warrants, net of offering costs	15,820			$ 6			15,814
Issuance of common stock upon exercise of convertible notes (shares)				486,923
Issuance of common stock upon exercise of convertible notes	1,737			$ 1			1,736
Issuance of common stock upon exercise of warrants (shares)				20,000
Issuance of common stock upon exercise of warrants	46						46
Elimination of cumulative translation adjustment upon deconsolidation of former French Subsidiaries	(641)									(641)
Net loss	(16,938)										(16,938)
Ending balance (shares) at Dec. 31, 2013				37,541,404
Ending balance at Dec. 31, 2013	10,972			$ 38			279,000			0	(268,066)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock to employees and Board of Director members (shares)				26,728
Issuance of restricted stock to employees and Board of Director members	0
Stock-based compensation expense	1,731						1,731
Issuance of common stock, net of offering costs (shares)						3,600,070
Issuance of common stock, net of offering costs			$ 5,904			$ 3			$ 5,901
Issuance of common stock and warrants, net of offering costs (shares)				3,570,030
Issuance of common stock and warrants, net of offering costs	6,050			$ 3			6,047
Repurchase and retirement of stock (shares)				(19,338)
Repurchase and retirement of stock	$ (42)						(42)
Return of common stock in connection with contract settlement (shares)	(388,888)			(388,888)
Return of common stock in connection with contract settlement	$ (910)						(910)
Net loss	(21,786)										(21,786)
Ending balance (shares) at Dec. 31, 2014				44,330,006
Ending balance at Dec. 31, 2014	1,919			$ 44			291,727			0	(289,852)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	1,210						1,210
Issuance of common stock and warrants, net of offering costs (shares)				6,043,955
Issuance of common stock and warrants, net of offering costs	$ 5,867			$ 6			5,861
Stock options exercises (shares)	40,520			40,520
Stock options exercises	$ 83			$ 0			83
Net loss	(19,023)										(19,023)
Ending balance (shares) at Dec. 31, 2015				50,414,481
Ending balance at Dec. 31, 2015	$ (9,944)			$ 50			$ 298,881			$ 0	$ (308,875)